J&J chief scientific officer interview on coronavirus vaccine trials - Business Insider

The leading coronavirus vaccines will soon face their biggest test yet: seeing if they actually work.

The biggest challenge in running these trials is enrolling people in areas with high rates of infection, J&J's Chief Scientific Officer Paul Stoffels told Business Insider. And Johnson & Johnson, the world's largest healthcare company, is aiming to start a late-stage study in September that could enroll between 30,000 and 100,000 people.

Drugmakers are preparing to chase the virus around the world. The higher the infection rate, the easier it is to determine how effective a vaccine is. If you test your vaccine in a coronavirus hot spot, study results will come sooner, Stoffels said. now planning to start initial human testing of its vaccine in July

"We don't know yet," Stoffels said, adding that it depends on how quickly the virus is spreading in areas where the vaccine is being tested. . But most of those research programs lack the resources that AstraZeneca, Pfizer, J&J, and Moderna possess.

Sadly looks like they may be recruiting on The UK or USA since our leaders Boris and Donald Trump do t seem to have got the problem contained

I'm so ashamed of myself for noticing.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Inside story of Brex layoffs after $150 million raise - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »